Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Hanmi tests Palpal for ischemic stroke
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Jul 31, 2013 11:13:47
The Ministry of Food and Drug Safety approved Hanmi’s protocol to test Palpal (sildenafil) as the treatment of ischemic stroke, the MOFDS said Monday.

Researchers in Bundang Seoul National University Medical Center will conduct the clinical trial to find out if Papal chewable 25mg helps blood circulation in the brain.

Currently researchers in Ilsan Hospital under National Health Insurance Service are conducting another study with Palpal as the treatment of prostate enlargement. Cialis is the only erectile dysfunction drug that is also approved for benign prostate hyperplasia.

If those studies show positive results, Hanmi seems to conduct more studies to add new indications. Palpal is the best-selling erectile dysfunction drug in South Korea, beating Pfizer’s Viagra.
Reply 0
Name Password
Popular News
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com